Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Wirkung der Su-Jok-Therapie auf das Stillen (Sujok)

30. Oktober 2026 aktualisiert von: Aysegul Kilicli

The Effect of Su Jok Therapy on Breastfeeding Success, Breastfeeding Self-Efficacy and Perception of Insufficient Milk After Caesarean Section in Primiparous

There are many alternative methods to increase breast milk. In the literature, studies on Su Jok therapy applications are limited and no studies on increasing breast milk have been found. In Korean language, 'Su' means hand and 'Jok' means foot. Su Jok therapy is defined as a modern acupressure/acupuncture interpretation that utilises the body's independent communication systems on the hands and feet by applying various techniques such as massage, moxa (heating), needles, magnets and seeds to the reflection points on the hands and feet. Su Jok is an integrated therapy that incorporates many tried and trusted methods of oriental medicine

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

There are many alternative methods to increase breast milk. In the literature, studies on Su Jok therapy applications are limited and no studies on increasing breast milk have been found. In Korean language, 'Su' means hand and 'Jok' means foot. Su Jok therapy is defined as a modern acupressure/acupuncture interpretation that utilises the body's independent communication systems on the hands and feet by applying various techniques such as massage, moxa (heating), needles, magnets and seeds to the reflection points on the hands and feet. Su Jok is an integrated therapy that incorporates many tried and trusted methods of oriental medicine.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

60

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Eyalet/Yerleşke
      • Sanliurfa, Eyalet/Yerleşke, Türkei (türkiye), 63000
        • Şanlıurfa training and research hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

19 Jahre bis 35 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • primiparous women giving birth by caesarean section,
  • women aged 19-35,
  • breastfeeding women

Exclusion Criteria:

  • those who refused to participate in the research

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: su jok therapy;

su jok therapy; application of seeds placed at certain points on the palm of the hand every day for the first ten days after birth, every day to be kept in the hand for 4 hours.

Su Jok Therapy

Kein Eingriff: control group

control group, Su Jok will not be applied

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Breastfeeding Self-Efficacy Scale
Zeitfenster: Pre-test; before the first Su Jok intervention

It was developed by Dennis (2003). Its Turkish validity and reliability was conducted by Aluş Tokat et al. (2010). The scale consists of 14 items and is in five-point Likert type. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

Pre-test; before the first Su Jok intervention
Breastfeeding Self-Efficacy Scale
Zeitfenster: On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.

It was developed by Dennis (2003). Its Turkish validity and reliability was conducted by Aluş Tokat et al. (2010). The scale consists of 14 items and is in five-point Likert type. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.
Breastfeeding Self-Efficacy Scale
Zeitfenster: On the 10th day after cesarean section; after the last (10th) Su Jok intervention.

It was developed by Dennis (2003). Its Turkish validity and reliability was conducted by Aluş Tokat et al. (2010). The scale consists of 14 items and is in five-point Likert type. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. A minimum of 14 points and a maximum of 70 points can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

On the 10th day after cesarean section; after the last (10th) Su Jok intervention.
Breastfeeding Charting System: LATCH
Zeitfenster: Pre-test; before the first Su Jok intervention

It was developed by Jensen et al. (1994). Its Turkish validity and reliability was performed by Yenal and Okumuş (2003). LATCH includes five evaluation criteria and consists of the first letters of the English equivalents of these criteria. In the LATCH Scoring System, 0, 1 or 2 points are given for each criterion A minimum score of 0 and a maximum score of 10 can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

Pre-test; before the first Su Jok intervention
Breastfeeding Charting System: LATCH
Zeitfenster: On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.

It was developed by Jensen et al. (1994). Its Turkish validity and reliability was performed by Yenal and Okumuş (2003). LATCH includes five evaluation criteria and consists of the first letters of the English equivalents of these criteria. In the LATCH Scoring System, 0, 1 or 2 points are given for each criterion. A minimum score of 0 and a maximum score of 10 can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.
Breastfeeding Charting System: LATCH
Zeitfenster: On the 10th day after cesarean section; after the last (10th) Su Jok intervention.

It was developed by Jensen et al. (1994). Its Turkish validity and reliability was performed by Yenal and Okumuş (2003). LATCH includes five evaluation criteria and consists of the first letters of the English equivalents of these criteria. In the LATCH Scoring System, 0, 1 or 2 points are given for each criterion. A minimum score of 0 and a maximum score of 10 can be obtained from the scale. All items are positive. The higher the score obtained from the scale, the higher the breastfeeding self-efficacy.

On the 10th day after cesarean section; after the last (10th) Su Jok intervention.
Inadequate Milk Perception Scale
Zeitfenster: Pre-test; before the first Su Jok intervention

The scale developed by McCarter-Spaulding and Kearney in 2001 consists of 6 questions to determine inadequate perception of breast milk. The first question questioning whether the mother perceives her milk as sufficient or not is in the form of 'yes' or 'no'. The other 5 questions aim to measure the perception of inadequacy of milk and are scored between 0-10. '0' indicates that milk is perceived as completely inadequate and "10" indicates that milk is perceived as completely adequate. The scale is scored between 0-50. A high score indicates an increased perception of milk sufficiency.

Pre-test; before the first Su Jok intervention
Inadequate Milk Perception Scale
Zeitfenster: On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.

The scale developed by McCarter-Spaulding and Kearney in 2001 consists of 6 questions to determine inadequate perception of breast milk. The first question questioning whether the mother perceives her milk as sufficient or not is in the form of 'yes' or 'no'. The other 5 questions aim to measure the perception of inadequacy of milk and are scored between 0-10. '0' indicates that milk is perceived as completely inadequate and "10" indicates that milk is perceived as completely adequate. The scale is scored between 0-50. A high score indicates an increased perception of milk sufficiency.

On the 3rd day after cesarean section (72 hours postpartum), before the 3rd Su Jok intervention.
Inadequate Milk Perception Scale; before the 3rd Su Jok intervention
Zeitfenster: On the 10th day after cesarean section; after the last (10th) Su Jok intervention.

The scale developed by McCarter-Spaulding and Kearney in 2001 consists of 6 questions to determine inadequate perception of breast milk. The first question questioning whether the mother perceives her milk as sufficient or not is in the form of 'yes' or 'no'. The other 5 questions aim to measure the perception of inadequacy of milk and are scored between 0-10. '0' indicates that milk is perceived as completely inadequate and "10" indicates that milk is perceived as completely adequate. The scale is scored between 0-50. A high score indicates an increased perception of milk sufficiency.

On the 10th day after cesarean section; after the last (10th) Su Jok intervention.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: AYŞEGÜL KILIÇLI, Assisstan. Prof. PhD., Muş Alparslan University

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. Oktober 2024

Primärer Abschluss (Tatsächlich)

20. Januar 2025

Studienabschluss (Tatsächlich)

20. Januar 2025

Studienanmeldedaten

Zuerst eingereicht

3. Oktober 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. Oktober 2024

Zuerst gepostet (Tatsächlich)

8. Oktober 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

30. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • MAUN

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

All

IPD-Sharing-Zeitrahmen

15 October 2024- 15 October 2025

IPD-Sharing-Zugriffskriterien

15 October 2024- 15 October 2025

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • ANALYTIC_CODE
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren